Clinical trial • Phase III • Oncology
Tucatinib for Breast cancer|Non-small cell lung carcinoma|Glioblastoma
Phase III trial of Tucatinib for Breast cancer|Non-small cell lung carcinoma|Glioblastoma. 20 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Breast cancer|Non-small cell lung carcinoma|Glioblastoma
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 10-07-2025
- First CTIS Authorization Date
- 15-10-2025
Trial design
Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 20
Recruitment
- Planned Sample Size
- 20
- Recruitment Window Months
- 24
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 20
Netherlands
- Earliest CTIS Part Ii Submission Date
- 10-10-2025
- Latest Decision Or Authorization Date
- 25-02-2026
- Processing Time Days
- 138
- Number Of Sites
- 1
- Number Of Participants
- 20
Sites
- Site Name
- Amsterdam UMC Stichting
- Department Name
- Clinical Pharmacology and Pharmacy
- Contact Person Name
- Imke Bartelink
- Contact Person Email
- i.bartelink@amsterdamumc.nl
- Number Of Participants
- 20
Sponsor
Primary sponsor
- Full Name
- Amsterdam UMC Stichting
- Organisation Type
- Patient organisation/association
- Country Of Registered Address
- Netherlands
Investigational products
- Investigational Product Name
- Tucatinib
- Active Substance
- Tucatinib
- Modality
- Small molecule
- Investigational Product Name
- Osimertinib
- Active Substance
- Osimertinib
- Modality
- Small molecule
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)